Recruiting

Testing new immune cells for treatment-resistant blood cancers

Plain-English translation of NCT05098613 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing , which are special immune cells taken from your body, modified in a laboratory to recognize and attack cancer cells, and then returned to your body. The study will evaluate whether this treatment is safe and what dose works best in teenagers and adults whose lymphoma has returned or stopped responding to previous treatments.

Many patients with blood cancers stop responding to standard treatments, leaving them with limited options. This medication targets cancer cells in a new way by using engineered immune cells, which may help patients whose cancer has become resistant to previous therapies.

Do you qualify?

You likely qualify if…

you are at least 16 years old (though the first three participants must be at least 18)
you have been diagnosed with relapsed or refractory B-cell lymphoma or mantle cell lymphoma that has progressed despite at least two prior treatments
your previous treatments included an anthracycline and anti-CD20 therapy (or for mantle cell lymphoma, a combination of specific approved drugs)
your cancer is measurable or evaluable by imaging and blood tests
you have no current signs of cancer in your brain or spinal cord (though you may be eligible if you were previously treated for brain involvement with no current evidence of disease)

You likely don't qualify if…

you have active or untreated cancer in your brain or central nervous system (unless it has been previously treated with no evidence remaining)
you have certain serious infections or uncontrolled medical conditions that would make treatment unsafe
you are pregnant or nursing
you have had certain prior treatments that might interfere with this new therapy

What participation looks like

You will receive chemotherapy to prepare your body, then undergo a procedure to collect your immune cells. These cells will be sent to a laboratory where they are modified and grown over several weeks. Once ready, the modified cells will be infused back into your body through an IV. You'll then be monitored closely during multiple visits over several months and up to one year to check how well the treatment works and manage any side effects.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Colorado Hospital, Aurora, Colorado